Clinical-stage biopharmaceutical company Omeros has reported positive data from the multiple-ascending-dose (MAD) portion of its OMS824 Phase I trial to treat cognition-imparing diseases such as Huntington’s and schizophrenia.

According to the data, the lead compound in Omeros‘ phosphodiesterase 10 (PDE10) programme, OMS824, has greater brain activity without movement side-effects seen with other PDE10 inhibitors.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

OMS824, which selectively inhibits the enzyme PDE10 expressed in areas of the brain correlated to a range of diseases that affect cognition, was well-tolerated in the study.

Omeros chairman and chief executive officer Dr Gregory Demopulos said OMS824 is able to achieve significantly higher concentrations at the target enzyme in the brain, without incurring the movement abnormalities, than other PDE10 inhibitors being developed across the industry.

"OMS824, which selectively inhibits the enzyme PDE10 expressed in areas of the brain correlated to a range of diseases that affect cognition, was well-tolerated in the study."

"While wrapping up the Phase I programme, we are aggressively advancing OMS824 into Phase II trials," Demopulos said.

"Our initial focus will be Huntington’s disease, for which we will be requesting orphan drug as well as fast track designations from the FDA, and a Phase IIa trial in patients with schizophrenia is expected to follow shortly thereafter.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"In addition to our progress in the OMS824 programme, we plan to submit the NDA next quarter and the MAA mid-year for OMS302, our ophthalmic drug product, and we remain on track to advance our MASP-2 and PDE7 programs into the clinic in the coming months."

The randomised, double-blind, placebo-controlled, single and multiple-dose escalation study enrolled 64 healthy male subjects, 40 of which received a single dose and 24 received daily dosing for seven to 10 days.

A linear increase in pharmacokinetic parameters with dose was observed, along with long half-life.

At well-tolerated doses, OMS824 achieved concentrations expected to inhibit PDE10 and support continuing development for the treatment of central nervous system disorders.